Birdwatch Note Rating
2024-12-30 06:39:47 UTC - HELPFUL
Rated by Participant: 2F046C5F1F654569A2AE0FF3C3EBF3B80998F1C5830821AD9814C7D835CB08B7
Participant Details
Original Note:
Vivek, founder of Roivant (NASDAQ: ROIV), led a firm that developed FDA-approved drugs. Axovant, a Roivant subsidiary, worked on an Alzheimer’s drug that failed—a fate shared by 99% of such drugs. Neither Vivek nor Roivant sold Axovant shares before its failure. https://www.sec.gov/edgar/search/?r=el#/q=axovant&dateRange=custom&category=form-cat2&ciks=0001635088&entityName=Roivant%2520Sciences%2520Ltd.%2520(CIK%25200001635088)&startdt=2014-01-01&enddt=2024-12-30
All Note Details